Relevant bibliographies by topics / Acetazolamide

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Acetazolamide'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Acetazolamide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Acetazolamide"

1

Leaf, David E., and David S. Goldfarb. "Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness." Journal of Applied Physiology 102, no. 4 (April 2007): 1313–22. http://dx.doi.org/10.1152/japplphysiol.01572.2005.

Full text
Abstract:
Acetazolamide, a potent carbonic anhydrase (CA) inhibitor, is the most commonly used and best-studied agent for the amelioration of acute mountain sickness (AMS). The actual mechanisms by which acetazolamide reduces symptoms of AMS, however, remain unclear. Traditionally, acetazolamide's efficacy has been attributed to inhibition of CA in the kidneys, resulting in bicarbonaturia and metabolic acidosis. The result is offsetting hyperventilation-induced respiratory alkalosis and allowance of chemoreceptors to respond more fully to hypoxic stimuli at altitude. Studies performed on both animals and humans, however, have shown that this explanation is unsatisfactory and that the efficacy of acetazolamide in the context of AMS is likely due to a multitude of effects. This review summarizes the known systemic effects of acetazolamide and incorporates them into a model encompassing several factors that are likely to play a key role in the drug's efficacy. Such factors include not only metabolic acidosis resulting from renal CA inhibition but also improvements in ventilation from tissue respiratory acidosis, improvements in sleep quality from carotid body CA inhibition, and effects of diuresis.
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 694 (March 1998): 6. http://dx.doi.org/10.2165/00128415-199806940-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 764 (August 1999): 6. http://dx.doi.org/10.2165/00128415-199907640-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 1167 (September 2007): 5. http://dx.doi.org/10.2165/00128415-200711670-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 1170 (September 2007): 7. http://dx.doi.org/10.2165/00128415-200711700-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 1191 (March 2008): 5. http://dx.doi.org/10.2165/00128415-200811910-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 1154 (June 2007): 5. http://dx.doi.org/10.2165/00128415-200711540-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 1369 (September 2011): 7. http://dx.doi.org/10.2165/00128415-201113690-00018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 564 (August 1995): 4. http://dx.doi.org/10.2165/00128415-199505640-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Acetazolamide." Reactions Weekly &NA;, no. 568 (September 1995): 5. http://dx.doi.org/10.2165/00128415-199505680-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Acetazolamide"

1

Granizo, Patricia Elizabeth Rivas. "Avaliação da fotoestabilidade de acetazolamida e loratadina e da capacidade de fotoproteção de seus complexos com ciclodextrinas." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/9/9139/tde-18042013-154107/.

Full text
Abstract:
A fotoestabilidade é uma propriedade das moléculas que, quando utilizada como parâmetro farmacêutico, descreve como um fármaco responde à exposição à luz (solar ou artificial). No presente trabalho, foi avaliada a fotoestabilidade dos fármacos loratadina (LORA) e acetazolamida (ACZ) e de complexos LORA-ciclodextrinas. O estudo de fotoestabilidade de LORA (Capítulo 2) indicou que o fármaco é estável quando no estado sólido, porém, ocorre surgimento de coloração intensa. Por outro lado, quando em solução, observou-se degradação do fármaco, com surgimento de vários fotoprodutos denominados F1 a F15, dentre os quais foi possível identificar cinco compostos: F4 (C13H10N), F10 (C14H10CIN), F8 (C20H18CIN2O), F9 (C19H18CIN2) e F14 (C17H14CIN). A validação do método analítico CLAE, utilizado para quantificação de LORA em especialidades farmacêuticas (comprimidos e xaropes) é descrita no Capítulo 3. Na avaliação da fotodegradação forçada de formulações líquidas contendo LORA, foram degradados até 50% do fármaco. As formulações sólidas apresentaram-se fotoestáveis, observando-se perda de menos de 5% do fármaco. Não foram encontrados produtos de fotodegradação nas formulações, quando analisadas tal qual, obtidas do mercado. Dessa forma, as embalagens primárias garantiram sua estabilidade. A complexação de LORA com ciclodextrinas (Capítulo 4) mostrou-se um recurso bastante interessante para melhorar a fotoestabilidade do fármaco, uma vez que, após 12 horas de irradiação luminosa, é possível recuperar até 99% deste, quando na forma de complexo com γ-CD na proporção 1:1. Finalmente, o Capítulo 5 traz o método CLAE desenvolvido e validado para avaliação da acetazolamida (ACZ), o qual mostrou-se adequado para a quantificação do fármaco, obtendo-se ótima linearidade, precisão, exatidão e seletividade. Segundo as condições do guia Q1B, a ACZ se manteve estável quando submetida à radiação luminosa utilizando meios aquosos e no estado sólido. No entanto, a fotoestabilidade da ACZ foi afetada na presença de metanol, sendo possível quantificar três impurezas.
Photostability is a property of molecules that, when used as a pharmaceutical parameter, can describe how a drug responds to exposure to light (either solar or artificial). In this study, the photostability of the drugs loratadine (LORA) and acetazolamide (ACZ), as well as LORA-cyclodextrin complexes, was evaluated. A study of the photostability of LORA (Chapter 2) indicated that the drug is stable in its solid form, however intense coloring does occur. On the other hand, when in solution form, degradation of the drug was observed, with the appearance of several photoproducts that we labled F1 to F15, among which it was possible to identify five compounds: F4 (C13H10N), F10 (C14H10CIN), F8 (C20H18CIN2O), F9 (C19H18CIN2) and F14 (C17H14CIN). The validation of the analytical method by HPLC, used for the quantification of LORA in pharmaceutical products (tablets and syrups) is detailed in Chapter 3. In the evaluation of forced photodegradation of liquid formulations containing LORA, up to 50% of the drug was degraded. The solid formulations proved to be photostable, with a loss of less than 5% of the drug. No photodegradation products were found in the formulations when they were analyzed \"as is\" (the way they were obtained from the commercial market). Accordingly, their primary packaging protected their stability. The complexation of LORA with cyclodextrins (Chapter 4) proved to be an effective resource for improving the photostability of the drug, since, after 12 hours of luminous radiation, it was possible to recover up to 99% of the drug, when in the complex form with γ-CD, in the proportion 1:1. Finally, Chapter 5 describes the HPLC method developed and validated for the evaluation of acetazolamide (ACZ), which proved to be adequate for the quantification of the drug, with the attainment of optimal linearity, precision, exactness and selectivity. According to the conditions of the Q1B guideline, ACZ was stable when subjected to luminous radiation using aqueous means and in its solid state. However, the photostability of ACZ was affected by the presence of methanol, and we were able to quantify three impurities.
APA, Harvard, Vancouver, ISO, and other styles
2

Ahn, Christopher. "Synthesis of N-methyl acetazolamide and N-methyl methazolamide." Scholarship @ Claremont, 2018. http://scholarship.claremont.edu/cmc_theses/1831.

Full text
Abstract:
Exposing Amyloid Beta 1-42 to neurons causes cell death. When carbonic anhydrase inhibitors (e.g. methazolamide or acetazolamide) are introduced along with 1-42 in a similar experiment, cell apoptosis is disrupted. However, when non-CA inhibitors are tested, (e.g. the indole derivative melatonin), the same disruption occurs. Are these carbonic anhydrase inhibitors acting on the same or a different pathway? One way to study the molecular mechanisms of these small molecule inhibitors is to modify their chemical structure. In this sense, when acetazolamide is methylated, apoptosis is resumed (Fossati et al., 2016). Finding a way to create N-methyl acetazolamide and N-methyl methazolamide through methylation procedures will lead to a better understanding of the pathways involved in neuronal apoptosis triggered by the Abeta peptide.
APA, Harvard, Vancouver, ISO, and other styles
3

Steckley, James L. "Investigation into the genetic aspects of acetazolamide-responsive paroxysmal vestibulocerebellar ataxia." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp01/MQ32512.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

WRONIECKI, KRZYSZTOF. "Traitement de l'hydrocephalie a pression normale par l'acetazolamide." Lyon 1, 1992. http://www.theses.fr/1992LYO1M129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

GUELQUE, BERTRAND. "Acidose hypokaliemique iatrogene : a propos d'une observation d'intoxication percutanee a l'acetazolamide revelant une nephropathie interstitielle chronique medicamenteuse." Lille 2, 1988. http://www.theses.fr/1988LIL2M031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

MAZEREEUW, FRANCOIS. "Les lithiases urinaires induites par l'acetazolamide : a propos d'une observation." Lille 2, 1993. http://www.theses.fr/1993LIL2M163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Boulet, Lindsey. "Attenuation of hypoxic pulmonary vasoconstriction by acetazolamide and methazolamide : a randomized crossover study." Thesis, University of British Columbia, 2017. http://hdl.handle.net/2429/62522.

Full text
Abstract:
Context: Acetazolmaide (AZ) is used in the prophylactic treatment of altitude illnesses. AZ is also known to attenuate HPV and increase alveolar ventilation. Methazolamide (MZ) is an analog to AZ and its effects on ventilation and HPV are unknown. Objective. To determine if MZ can improve oxygenation and attenuate HPV to a similar extent as AZ in healthy humans exposed to poikilocapnic hypoxia. Design, Setting, Participants and Interventions: A randomized, placebo controlled, double-blinded trial was performed in healthy participants at the Cardiopulmonary Lab for Experimental and Applied Physiology. Prior to each of the three experimentation days, participants were administered one of three treatments (AZ, MZ, & placebo) at random for two days. Each treatment was separated by a 10-day washout period to avoid contamination from previous trials. During each trial, participants were exposed to poikilocapnic hypoxia (FIO2 ≈ 0.12) for 60 minutes. Primary Outcome Measures: Partial pressure of alveolar O₂ (PAO₂) represented oxygenation while pulmonary artery systolic pressure (PASP) and total pulmonary resistance (TPR) were chosen to represent the HPV response. Results: All participants (n = 11) completed all three trials. Change in Q̇ from baseline to hypoxia was not different between treatments. Change in PASP was significantly lower with the AZ (8.0 ± 0.7 mmHg) and MZ (9.0 ± 0.9 mmHg) treatments compared to placebo (PASP: 14.1 ± 1.3 mmHgP < 0.05). Change in PAO₂ was also decreased with both drug treatments (AZ: 54.8 ± 1.3 mmHg; MZ: 53.9 ± 1.3 mmHg) compared to placebo (48.5 ± 1.6 mmHg; P < 0.05). Conclusion: MZ attenuated HPV to the same degree as AZ. MZ also resulted in a similar improvement in PAO₂ as AZ during hypoxia compared to placebo. Trial Registration: This study was registered with the U.S. National Institutes of Health: NCT02760121 Funding: This project was funded by the Canadian Foundation for Innovation and by the Natural Science and Engineering Council of Canada.
Graduate Studies, College of (Okanagan)
Graduate
APA, Harvard, Vancouver, ISO, and other styles
8

RUNGE, ISABELLE. "Effets respiratoires de l'acetazolamide lors de l'alcalose de reventilation chez l'insuffisant respiratoire chronique." Lille 2, 1989. http://www.theses.fr/1989LIL2M096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Urbano, Charissa M. "Potentiating effects of caffeine on the teratogenicity of acetazolamide in two strains of mice." Virtual Press, 1988. http://liblink.bsu.edu/uhtbin/catkey/552944.

Full text
Abstract:
This study was designed to determine the effect of caffeine on the teratogenicity of acetazolamide in susceptible and resistant strains of inbred mice. The highly susceptible C57BL/6J and more resistant SWV strain were used. Pregnant C57BL/6J and SWV mice were treated with caffeine, low or high dose acetazolamide, or a combination of both agents during the sensitive period of development. Untreated and vehicle-treated groups served as controls. Individual fetuses were examined for gross morphological abnormalities and skeletal variations.Findings1. A highly significant (P<.001) increase in fetal malformations, especially right forelimb ectrodactyly, was evident in C57BL/6J litters exposed on day 9 of gestation to both agents when contrasted with those exposed to either agent alone. Both frequency and severity of ectrodactyly was potentiated by caffeine.2. The SWV strain was resistant to the interaction of caffeine and acetazolamide when treated on day 9 of gestation. However, a highly significant (P<.001) increase in the rate of fetal malformation was found in litters whose dams were treated with high dose acetazolamide and caffeine on day 8 of gestation. The most common malformations observed were exencephaly and umbilical hernia.3. No differences in maternal mortality, fetal weight, litter size, or embryo mortality could be attributed to treatment in either strain.4. Skeletal examination of the number of ossified cervical and caudal vertebral centra revealed a reduction in ossification among C57BL/6J litters exposed to high dose acetazolamide or acetazolamide plus caffeine. These same centers of ossification were mildly affected by treatment in the SWV strain. In both strains the first cervical vertebrae (Cl) appeared to provide the most sensitive index of teratogenic exposure.ConclusionsThis study provides evidence that a subteratogenic dose of caffeine can potentiate the teratogenic effect of acetazolamide in both C57BL/6J and SWV mice. However, strain associated, and therefore genetically based, differences in sensitivity were confirmed. Skeletal examinations provided evidence that treatment with both agents delayed fetal development in the more susceptible C57BL/6J strain, while reduction of ossification was less evident in the SWV strain. Thus, this parameter also reflects the greater resistance of the SWV strain to the interaction of acetazolamide and caffeine. Finally, these experiments support the idea that chemical interactions may, in part, be responsible for many birth defects of unknown etiology--a claim worthy of further investigation.
Department of Biology
APA, Harvard, Vancouver, ISO, and other styles
10

Ramos, Tercio Carneiro. "AvaliaÃÃo de eficÃcia e seguranÃa da acetazolamida na doenÃa periodontal experimental." Universidade Federal do CearÃ, 2010. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=5221.

Full text
Abstract:
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior
As doenÃas periodontais sÃo as principais causas de perda de dentes em adultos. O fator etiolÃgico preponderante para desencadear a periodontite à o acumulo do biofilme dental com predominÃncia de bactÃrias anaerÃbicas gram negativas. Apesar de ser de origem bacteriana a resposta inflamatÃria induzida a partir de fatores do hospedeiro pode influenciar na progressÃo e nas caracterÃsticas clÃnicas da doenÃa periodontal. A perda Ãssea alveolar à tÃpica na evoluÃÃo desta patologia e dependente da atividade osteoclÃstica. Por sua vez, um dos mecanismos de reabsorÃÃo Ãssea por estas cÃlulas à atravÃs da produÃÃo de prÃtons liberados nos vacÃolos de reabsorÃÃo pela atividade da anidrase carbÃnica. Tem sido relatado que inibidores desta enzima, como acetazolamida, tem aÃÃo supressora sobre osteoclastos. O objetivo deste estudo foi analisar o efeito da acetazolamida (ACTZ) na perda Ãssea induzida no modelo de periodontite experimental em ratos, bem como a dosagem de biomarcadores sÃricos do processo inflamatÃrio periodontal e anÃlise histolÃgica do periodonto. AnÃlises de seguranÃa tambÃm foram realizadas atravÃs de hemograma completo, dosagens de TGP, TGO, gama-GT e histopatologia de ÃrgÃos como: fÃgado, rins, baÃo, coraÃÃo e pulmÃo. Para avaliaÃÃo da perda Ãssea alveolar 50 ratos receberam ligaduras de nylon na regiÃo do segundo molar superior esquerdo. Os animais foram divididos em seis grupos: Grupo veÃculo (propilenoglicol) (n=9), grupo controle positivo (alendronato 0,08 mg/Kg) (n=7), grupo controle negativo (salina) (n=9) e grupos que receberam acetazolamida via I.P. nas doses (8,3, 25 e 75 mg/Kg [grupos ACTZ8,3, ACTZ25 e ACTZ75, respectivamente] n= 7, 9 e 9). ApÃs 11 dias, os ratos foram mortos. A perda Ãssea alveolar foi avaliada macroscopicamente atravÃs da Ãrea de exposiÃÃo de raiz. Em outros quatro grupos, ACTZ25 (n=5) e veÃculo (n=5), o periodonto foi analisado histologicamente apÃs 11 e 17 dias de ligadura por coloraÃÃo em HE. Biomarcadores sÃricos foram dosados (IL-1, IL-4, fractalkine, CINC-2, CINC-3, LIX, GM-CSF, βNGF, VEGF e CNTF) atravÃs da tÃcnica de microarray antes e depois da ligadura em trÃs grupos; ACTZ25, Veiculo e Sham (cirurgia simulada). No grupo de ACTZ25 foi realizada a anÃlise de seguranÃa (alpha=5%). Macroscopicamente, o grupo alendronato (controle positivo) apresentou a menor perda Ãssea, seguido do grupo ACTZ75 e ACTZ25 (p<0.05) quando comparados aos controles veÃculo e salina que nÃo diferiram entre si (p>0.05). Histologicamente, o grupo ACTZ apresentou a menor reabsorÃÃo de osso e cemento (p<0,05) apÃs 17 dias de ligadura, nÃo houve diferenÃa entre o grupo ACTZ25 e o veÃculo quanto ao infiltrado inflamatÃrio (P>0,05) . As maiores concentraÃÃes de IL-4 e CNTF foram observadas no grupo ACTZ25 (p< 0,05) quando comparado ao grupo veÃculo. As anÃlises de seguranÃa demonstraram que acetazolamida na dosagem de 25 mg/Kg foi bem tolerada sem alteraÃÃes significativas do hemograma, nas enzimas hepÃticas e histopatologia dos ÃrgÃos pesquisados. ConcluÃmos que a acetazolamida pode proteger o periodonto da reabsorÃÃo Ãssea induzida por ligadura em ratos e pode estar associada a mediadores envolvidos com o reparo, como a IL-4 e CNTF, alÃm de ser bem tolerada.
Periodontal diseases are the main cause of tooth loss in adults. The preponderant etiologic factor for the onset of periodontitis is the accumulation of dental biofilm with predominance of anaerobic gram negative bacteria. In spite of being of bacterial origin, the inflammatory response induced by factors in the host may influence the progression and clinical characteristics of periodontal disease. Alveolar bone is typical in the development of this pathology and is dependent on osteoclastic activity. In turn, one of the mechanisms of bone resorption by these cells is through the production of protons released in the resorption vacuoles by carbonic anhydrase activity. It has been reported that carbonic anhydrase inhibitors, such as acetazolamide, have a suppressive action on osteoclasts. The aim of this study was to analyze the effect of acetazolamide (ACTZ) on bone loss induced in the experimental periodontitis model in rats, as well as the dosage of seric biomarkers in the periodontal inflammatory process and histologic analysis of the periodontium. Safety analyses were also performed by means of a complete hemogram, biochemical tests for TGP, TGO, gama-GT and histopathology of organs such as: the liver, kidneys, spleen, heart and lungs. To evaluate alveolar bone loss, 50 rats received nylon ligatures in the maxillary left second molar region. The animals were divided into six groups: Vehicle Group (propylenoglycol) (n=9), Positive Control Group (alendronate 0.08 V (n=7), Negative Control Group (saline) (n=6) and Groups that received acetazolamide I.P. in the following doses: (8.3, 25 and 75 mg/Kg [Groups ACTZ8,3, ACTZ25 and ACTZ75 respectively] n= 7, 9 and 9). After 11 days, the rats were sacrificed. Alveolar bone loss was macroscopically evaluated by means of the area of root exposure. In another four groups, ACTZ25 (n=5) and vehicle (n=5), the periodontium was histologically analyzed after 11 and 17 days of ligature, by HE staining. Seric biomarkers were dosed (IL-1, IL-4, fractalkine, CINC-2, CINC-3, LIX, GM-CSF, βNGF, VEGF and CNTF) by means of the microarray technique before and after ligature in three groups; ACTZ25, Vehicle and Sham (simulated surgery). In the ACTZ25 group, safety analysis was performed (alpha=5%). Macroscopically, the alendronate Group (positive control) presented the lowest bone loss, followed by Groups ACTZ75 and ACTZ25 (p<0.05) when compared with the vehicle and saline controls, which did not differ between them (p>0.05). Histologically, the ACTZ group presented the lowest bone and cement resorption (p<0.05) after 17 days of ligature, and there was no difference between the ACTZ25 and vehicle groups with regard to inflammatory infiltrate (P>0.05). The highest concentrations of IL-4 and CNTF were observed in Group ACTZ25 (p< 0.05) when compared with the vehicle group. The safety analyses demonstrated that acetazolamide at the dose of 25 mg/Kg was well tolerated without significant alterations in the hemogram, hepatic enzymes and histopathology of the researched organ. It was concluded that acetazolamide may protect the periodontium from bone resorption induced by ligature in rats, and may be associated with mediators involved in repair, such as IL-4 and CNTF, in addition to being well tolerated.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Acetazolamide"

1

Siddique, M. The estimation of acetazolamide in saliva. Bradford, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cardiovascular and thermoregulatory impairment during submaximal exercise with acetazolamide. 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cardiovascular and thermoregulatory impairment during submaximal exercise with acetazolamide. 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Grissom, Colin Kerst. Acetazolamide in the treatment of acute mountain sickness: Clinical efficacy and effect on gas exchange. [New Haven :bs.n.], 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Turney, Ben, and John Reynard. Kidney stones. Edited by John Reynard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0013.

Full text
Abstract:
The composition of kidney stones is variable and the predisposing factors multifactorial. Consequently, a detailed evaluation of the patient’s lifestyle, diet, fluid intake, medical history, drug history, urinary tract anatomy, blood, and urine biochemistry and stone composition is required determine predisposing factors for stone formation in an individual patient. Combinatorial subtle variants in biochemistry may act synergistically to increase risk of stone formation/recurrence. Many medications may alter blood and/or urine biochemistry and predispose to stone formation. Corticosteroids increase absorption of calcium from the gut and cause hypercalciuria. Topirimate (for seizures or migraines), sulphasalazine (for rheumatoid arthritis), diuretics containing triamterene, acetazolamide (for myotonia), antacids containing trisilicate, calcium supplements, vitamin D supplements, vitamin C in high doses, indinavir (for HIV), and some herbal medicines (containing ephedrine) all increase stone risk.
APA, Harvard, Vancouver, ISO, and other styles
6

Martin, Daniel S., and Michael P. W. Grocott. Pathophysiology and management of altitude-related disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0350.

Full text
Abstract:
Acute high-altitude related illnesses include acute mountain sickness (AMS), high altitude pulmonary oedema (HAPO) and high altitude cerebral oedema (HACO). AMS is characterized by headache, lack of appetite, poor sleep, lethargy, and fatigue. AMS is a common, generally benign, self-limiting condition if managed with rest, no ascent, and symptomatic treatment. Descent is indicated in severe cases. HACO and HAPO are rare, but serious conditions that should be considered life-threatening medical emergencies. HACO is characterized by the presence of neurological signs (including confusion) at altitude, commonly in the presence of headache. HAPO is characterized by breathlessness and signs of respiratory distress at altitude, particularly accompanying exercise. Management of HACO and HAPO involves urgent descent, supplemental oxygen (cylinder, concentrator, or portable hyperbaric chamber) if available, and specific treatment with dexamethasone (HACO) or nifedipine (HAPO). Slow controlled ascent (adequate acclimatization) is the best prophylaxis against the acute high-altitude-related illnesses. Acetazolamide is an effective prophylaxis against AMS.
APA, Harvard, Vancouver, ISO, and other styles
7

Brimioulle, Serge. Pathophysiology, causes, and management of metabolic alkalosis in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0257.

Full text
Abstract:
Metabolic alkalosis occurs in up 51% of abnormal acid-base samples in the hospital. It is characterized by a primary increase in bicarbonate concentration and is always associated with chloride depletion. In critically-ill patients, it is most often generated by diuretic administration, digestive losses, alkali administration, or rapid correction of hypercapnia. Even after all causal factor are removed, it can be maintained by blood volume depletion and potassium depletion. Metabolic alkalosis results in hypercapnia, hypoxaemia, cardiac arrhythmias, altered consciousness, and neuromuscular hyperexcitability. It is first treated by removing the causal factors, whenever possible. Maintaining factors must be reversed by sodium chloride and/or potassium chloride administration. Acetazolamide and renal replacement therapy, when given for specific indications, can also correct the alkalosis. Lysine and arginine chloride are no longer used. If metabolic alkalosis is severe or when other treatments are contraindicated or ineffective, hydrochloric acid infusion is useful. Dilute hydrochloric acid can be infused safely, provided adequate precautions are taken to prevent extravascular leakage, vessel damage, and tissue necrosis.
APA, Harvard, Vancouver, ISO, and other styles
8

Koeberle, Bernhard. Wirkung von Acetazolamid auf den Hirnkreislauf des Menschen. 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Luedtke, Thomas. Reservekapazität der Gehirndurchblutung unter Kohlendioxid-Inhalation und Acetazolamid. 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Acetazolamide"

1

Patsalos, P. N. "Acetazolamide." In Antiepileptic Drug Interactions, 5–9. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2434-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patsalos, P. N. "Acetazolamide." In Antiepileptic Drug Interactions, 197. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2434-4_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Panayiotopoulos, C. P. "Acetazolamide." In Antiepileptic Drugs, Pharmacopoeia, 1–4. London: Springer London, 2010. http://dx.doi.org/10.1007/978-0-85729-012-0_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patsalos, Philip N. "Acetazolamide." In Antiepileptic Drug Interactions, 7–10. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32909-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Patsalos, Philip N. "Acetazolamide." In Antiepileptic Drug Interactions, 153. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32909-3_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hovinga, Collin A. "Acetazolamide." In Atlas of Epilepsies, 1707–11. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84882-128-6_259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Neufeld, Miri Y. "Acetazolamide." In The Treatment of Epilepsy, 376–87. Oxford, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118936979.ch28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patsalos, Philip N. "Acetazolamide." In Antiseizure Medication Interactions, 31–33. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-82790-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

de Groot, Anton C. "Acetazolamide." In Monographs In Contact Allergy, 55–56. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Noujaim, Daniel Lopes, Juan E. Small, and Daniel Thomas Ginat. "Acetazolamide (Diamox)." In Neuroimaging Pharmacopoeia, 309–12. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12715-6_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Acetazolamide"

1

Storarri, Ana Carolina Montouro, Annelise Akemi Higa Lee, and Renan Barros Domingues. "Effect and tolerance of acetazolamide in patients with idiopathic intracranial hypertension." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.766.

Full text
Abstract:
Introduction: Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH). The Idiopathic Intracranial Hypertension Treatment Trial showed a modest improvement in visual field function in patients using acetazolamide with a low-sodium weight-reduction diet compared with diet alone. There is still insufficient data to establish its use. Objectives: To describe acetazolamide effect in improving headache, visual acuity and papilloedema in patients with HII and assess patient’s tolerance to it Design. Retrospective analysis of 37 patients with IIH taking acetazolamide in a headache clinic of a tertiary medical center in São Paulo, Brazil. Results: The population analyzed was mostly female, with a mean age of 34.32 years, obese with a mean body mass index of 34.16, and were referred to the headache clinic from the emergency department. All 37 patients complained of headache and had increased cerebrospinal fluid opening pressure initially (mean 42.05). Improvement of headache was reported by 25 (67.56%) patients. Fundoscopy was described in the initial and last visit in 24 patients: 15 had papilloedema initially and 9 had a normal exam. At the last visit 9 patients improved (60%), 6 maintained papilloedema and 1 patient developed it. Visual acuity was described in the initial and last visit in 20 patients: 5 had normal visual acuity, 14 had low visual acuity and one patient was amaurotic. Of those with low visual acuity 2 (14.28%) got completely recovered, 5 (35.71%) recovered partially and 7 (50%) got worse. Two patients with the initial normal exam got worse during follow-up. Adverse effects were reported by 5 (13.51%) patients and led to discontinuation of acetazolamide — 3 of 5 reported paresthesias. Conclusion: Acetazolamide reduced headache in 67.56%, improved visual acuity in 50% and papilloedema in 60%, and was well tolerated by 86.48% of patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Edwards, Bradley A., Danny J. Eckert, Amy S. Jordan, Atul Malhotra, Lauren Hess, Karen Stevenson, David P. White, and Andrew Wellman. "Effect Of Acetazolamide In Obstructive Sleep Apnea." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Medeiros, Lorrana Alves, and Carla Cristina Lopes Barbosa Tiveron. "Clinical treatment of Idiopathic Benign Intracranial Hypertension (IIH): case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.020.

Full text
Abstract:
Introduction: Headache is one of the most common complaints in medicine, being divided into primary or secondary. Idiopathic Benign Intracranial Hypertension (IBIH) is one of the causes of secondary headache, where there is an increase in intracranial pressure in the absence of an expansive process. Goals: To present the management of IBIH refractory to conventional treatment. Methodology: Clinical evaluation of the patient, review of her medical record and review of literature related to the topic. Case report: RMC, female, 55 years old, short stature, BMI 48, presented in 2018 repetitive pictures of severe headache, without improvement factors, associated with visual disturbances that evolved to amausore, sporadic loss of balance and slowing pupillary reflexes, mood disorders and easy cry. Magnetic resonance and fundscopy were inconclusive, and CSF puncture found an opening pressure of 20 cm of water. After CSF puncture, the patient showed instantaneous vision improvement, and therapy with Acetazolamide was introduced, which controlled and kept her ophthalmological symptoms stable. Angina conditions were only resolved with the introduction of Lamotrigine. RESULTS: The most commonly prescribed medication for IBIH, Acetazolamide, controlled the reported patient’s ophthalmological condition, but not the pain episodes. When this medication alone cannot control the condition, the association of other medications or surgical conduct is indicated. The association of Acetazolamide with Lamotrigine was extremely important to solve the patient’s pain episodes, making her clinical management positive. Conclusion: The combination of Lamotrigine and Acetazolamide has been shown to be an excellent form of outpatient treatment for IBIH.
APA, Harvard, Vancouver, ISO, and other styles
4

Green, Jack, and Pooja Nawathe. "Acetazolamide-Exacerbated Acute Flaccid Paralysis And Toxic-Metabolic Encephalopathy." In AAP National Conference & Exhibition Meeting Abstracts. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/peds.147.3_meetingabstract.417-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Giles, Rachel. "Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion." In ESC Congress 2022, edited by Marc Bonaca. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/caab19d5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Edwards, Bradley A., Robert L. Owens, Danny J. Eckert, Scott A. Sands, David P. White, Atul Malhotra, and Andrew Wellman. "Effect Of Acetazolamide On Upper Airway Collapsibility In Obstructive Sleep Apnea." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2721.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hellemans, S., E. Van De Perck, D. Van Loo, M. Dieltjens, J. Verbraecken, S. Op De Beeck, and O. M. Vanderveken. "Optimal Dose and Efficacy of Acetazolamide as Obstructive Sleep Apnea Treatment." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rastogi, R., K. A. Bakkila, M. S. Badr, and S. Chowdhuri. "Effect of Acetazolamide on Pathophysiology of Sleep Disordered Breathing in Older Adults." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Furian, Michael, Aline Buergin, Philipp M. Scheiwiller, Laura Mayer, Simon Schneider, Maamed Mademilov, Berik Emilov, et al. "Prevention of altitude-related illness in patients with COPD by acetazolamide. RCT." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3938.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Andreieva, I. "Effectiveness of acetazolamide in patients with moderate obstructive sleep apnea and obesity." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.3872.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Acetazolamide"

1

Hariswar, Pari Thenmozhi, Ramanathan Venkateswaran, George Melvin, kshirsagar Shivani, and M. Rajeswari. Acetazolamide in weaning from mechanical ventilation in hypercapnic respiratory failure. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2023. http://dx.doi.org/10.37766/inplasy2023.7.0108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Acetazolamide' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography